^
    2years
    A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Silverback Therapeutics | N=225 --> 0 | Trial completion date: May 2025 --> Mar 2022 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2025 --> Mar 2022
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    HER-2 negative • NECTIN4 expression
    |
    Keytruda (pembrolizumab) • SBT6290
    2years
    A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=225, Recruiting, Silverback Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    HER-2 negative • NECTIN4 expression
    |
    Keytruda (pembrolizumab) • SBT6290
    over2years
    A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=225, Not yet recruiting, Silverback Therapeutics
    New P1/2 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    HER-2 negative • NECTIN4 expression
    |
    Keytruda (pembrolizumab) • SBT6290
    3years
    [VIRTUAL] SBT6290, a systemically administered Nectin4-directed TLR8 ImmunoTAC™ product candidate, is designed for tumor-localized activation of myeloid cells (AACR 2021)
    Systemic administration of a SBT6290 surrogate in mice bearing Nectin4-expressing tumors results in intra-tumoral myeloid and T cell activation and increased overall survival. The preclinical data described here demonstrate the potential for SBT6290 to drive anti-tumor responses and support continued preclinical development of SBT6290 for Nectin4-expressing tumors.
    IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TLR8 (Toll Like Receptor 8)
    |
    NECTIN4 expression
    |
    SBT6290